Eli Lilly Unveils Another Round of Lower-Cost Insulin Products was reported by Alex Keown bor BioSpace.com, 15 January 2020. 

Eli Lilly is adding additional reduced cost insulin options to patients. The Indianapolis-based company announced lower-priced versions of Humalog Mix75/25 KwikPen (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog Junior KwikPen (insulin lispro injection 100 units/mL).

Both of the insulin products will be marked at 50% cheaper compared to the branded versions and will be available by mid-April, Eli Lilly said. These insulins are identical molecules to the branded versions and may be substituted at the pharmacy counter, Eli Lilly said in its announcement.

This is Eli Lilly’s second attempt at introducing lower-cost insulins. In May of last year, two months after its regulatory approval, the company’s authorized generic version of Humalog hit the streets with a price tag 50% cheaper than its branded life-saving insulin. However, in August, an analysis showed that patients were not getting the less-expensive version due to a number of different reasons, including a lack of awareness of the product.

Read more:  Eli Lilly Unveils Another Round of Lower-Cost Insulin Products

  • Omnipod Horzon Coming to Market Second Half of This Year, announced at the 38th Annual JP Morgan Healthcare conference, Westin St. Francis Hotel, San Francisco, CA, 14 January 2020.  Insulet reconfirmed their Horizon market target date of the 2nd half of 2020 (exciting news, just remember that December 31st is in the 2nd half of 2020), and will be controlled by your cell phone (or included PDA). View presentation:  http://investor.insulet.com/static-files/047f83db-e834-414e-a69e-81364914a68f

One Less Device: Combining CGM and Insulin Infusion—JDRF Clinical Trial was announced by JDRF, 9 December 2019.

JDRF is funding work to build a better insulin infusion set; the current infusion sets can be uncomfortable and unreliable, and need to be changed every two to three days. One partner is Pacific Diabetes Technologies, who will test its all-in-one continuous glucose monitoring (CGM) sensor and infusion set in people with type 1 diabetes (T1D) in a clinical trial at St. Vincent’s Hospital in Melbourne, Australia, under David O’Neal, M.D. The device, it is hoped, will eliminate the need for pump users to stick themselves twice—once to insert their CGM sensors, and again to insert their infusion catheters—improving the performance of both functions and making insulin dosing more accurate and comfortable. By making CGM a feature on an infusion set, it will also cut the number of devices worn on the body from two to one. Future versions will also offer an option to work with needleless Smart Pens for those who prefer multiple daily injections (MDI).


Read more:  Combining CGM and Insulin Infusion—JDRF Clinical Trial


Share This
Skip to content